At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 455 enrolled
Drug / intervention
PF-06410293 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A RANDOMIZED COMPARATIVE STUDY ASSESSING THE SWITCHING BETWEEN PF-06410293 AND HUMIRA (REGISTERED) IN COMBINATION WITH METHOTREXATE IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS
In Brief
A Phase 3 clinical trial evaluating PF-06410293 and adalimumab for Rheumatoid Arthritis. Completed, enrolled 455 participants across 72 sites in 10 countries.
Detailed Summary
The study will assess the impact of pharmacokinetics (PK), safety and immunogenicity after switches between PF-06410293 and adalimumab and with continuous dosing with adalimumab in combination with methotrexate in subjects with moderately to severely active rheumatoid arthritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesBosnia and Herzegovina, Bulgaria, Czechia, Lithuania, Poland, Russia, Serbia, South Africa, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
Enrollment StartJan 2020
First PostedJan 2020
Primary CompletionJun 2021
TodayJul 2026
First PostedJan 18, 2020
Enrollment StartJan 13, 2020
Primary CompletionJun 22, 2021
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 6.5 years ago
Interventions
PF-06410293drug
SC injection
adalimumabdrug
SC injection